NBR Polska Tomasz Kłodawski

The site is conducting research focused on Atrial Fibrillation, aiming to test a novel therapy that may lower the risk of stroke and systemic embolism while also assessing bleeding safety compared with existing treatment.

• Stroke and systemic embolism prevention
• Bleeding risk assessment
• Comparative effectiveness versus standard anticoagulant

NBR Polska Tomasz Kłodawski in Warsaw supports these cardiovascular investigations, contributing expertise from three investigators across two trials.

Studies are evaluating the impact of a new agent on adults with overweight or obesity without diabetes, with the goal of achieving meaningful body weight loss and improving metabolic health.

• Body weight reduction efficacy
• Metabolic parameter improvement
• Safety and tolerability profiling

These trials at NBR Polska Tomasz Kłodawski add to the growing portfolio of metabolic research conducted in Warsaw, involving a dedicated team of investigators.